SUBSCRIBE
SUBSCRIBE

GLP-1

A Novo Nordisk flag flies in the wind/Courtesy jor
Business
Novo Nordisk Lays Off 185 Employees, Hiring 70 in Commercial Reorg
After falling short of analysts’ expectations in its latest quarter, Novo Nordisk is restructuring its commercial operations as it looks to fend off challenges to its products.
November 13, 2017
 · 
2 min read
 · 
Alex Keown
Business
Secretive Moderna Inks mRNA Heart Failure Deal With AstraZeneca
The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
November 1, 2017
 · 
4 min read
Biotech Beach
Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Inborn Errors of Metabolism at The Liver Meeting 2017 (AASLD)
This data will be presented by Vaidehi Joshi, Scientist I, Therapeutics, at Organovo.
October 20, 2017
 · 
7 min read
A Novo Nordisk flag flies in the wind/Courtesy jor
FDA
Eli Lilly Looks Over Its Shoulder After Novo Nordisk Wins FDA Panel Backing for Diabetes Drug
An advisory panel with the FDA gave a near unanimous support to Novo Nordisk’s diabetes drug semaglutide, a long-acting GLP-1 analogue.
October 19, 2017
 · 
2 min read
 · 
Alex Keown
Ablynx Seals Nanobody R&D Deal Worth $2.8 Billion With Drug Giant Sanofi
Business
Sanofi R&D Boss Thinks His Team is Ready to Survive Without Besties Regeneron and Alnylam
September 21, 2017
 · 
2 min read
Harmony Biosciences Gains U.S. Rights to Pitolisant, Raises $270 Million
Business
Biotech Gene Therapy Startup Apic Bio Launches in Cambridge, Massachusetts
August 22, 2017
 · 
2 min read
Novo Nordisk A/S’s Diabetes Drug Beats Out Eli Lilly’s Trulicity in Phase III Trials
Drug Development
Novo Nordisk A/S’s Diabetes Drug Beats Out Eli Lilly’s Trulicity in Phase III Trials
August 17, 2017
 · 
2 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Drug Development
Galapagos’ Phase II Results With GLPG1690 are ‘Extremely Exciting’
August 10, 2017
 · 
2 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Business
Dimension Therapeutics Pink Slips 25% of Workforce
June 27, 2017
 · 
2 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Business
Fast-Growing Intarcia Awaits Crucial FDA Decision in New Boston HQ
May 8, 2017
 · 
3 min read
Load More
PRESS RELEASES
Press Releases
Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways
December 29, 2025
 · 
19 min read
Press Releases
FDA approves Novo Nordisk’s Wegovy® pill, the first and only oral GLP-1 for weight loss in adults
December 23, 2025
 · 
14 min read
Press Releases
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
December 23, 2025
 · 
4 min read
Press Releases
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
December 19, 2025
 · 
9 min read
Press Releases
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
December 18, 2025
 · 
24 min read
Press Releases
Confo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric Hypoglycemia
December 18, 2025
 · 
4 min read
Press Releases
Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
December 18, 2025
 · 
15 min read
Press Releases
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
December 17, 2025
 · 
21 min read
Press Releases
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
December 12, 2025
 · 
5 min read
Press Releases
Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies
December 11, 2025
 · 
5 min read
Press Releases
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
December 8, 2025
 · 
14 min read
Press Releases
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
December 8, 2025
 · 
12 min read
Press Releases
Ascletis’ Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
December 8, 2025
 · 
7 min read
Press Releases
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
December 8, 2025
 · 
1 min read
Press Releases
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
December 2, 2025
 · 
10 min read
Press Releases
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
December 1, 2025
 · 
4 min read
Press Releases
Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
November 27, 2025
 · 
3 min read
Press Releases
Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096
November 27, 2025
 · 
6 min read
Press Releases
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
November 26, 2025
 · 
6 min read
Press Releases
Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes
November 25, 2025
 · 
5 min read
Load More